NABTC Promotes First Brain Tumor Awareness Week

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 11
Volume 6
Issue 11

NEW YORK-The North American Brain Tumor Coalition (NABTC) kicked off the first Brain Tumor Awareness Week, October 19 to 25, 1997. The national event is designed to educate the public about the impact of brain tumors, as well as highlight the need for increased research funding.

NEW YORK—The North American Brain Tumor Coalition (NABTC) kicked off the first Brain Tumor Awareness Week, October 19 to 25, 1997. The national event is designed to educate the public about the impact of brain tumors, as well as highlight the need for increased research funding.

Said Susan Weiner, PhD, chair of the NABTC, “Our goal is to draw greater attention to a debilitating and often fatal disease for which the causes are still uncertain.” Each year, she said, approximately 100,000 people in the United States will be diagnosed with a primary or metastatic brain tumor.

To raise awareness about the need for increased research funding on Capitol Hill, the NABTC scheduled a Congressional Luncheon to take place during Brain Tumor Awareness Week.

The NABTC is also issuing a Patient Resource Guide during Brain Tumor Awareness Week to help connect brain tumor patients and their families with the various support services, informational materials, and programs provided by the coalition’s eight member organizations. A free copy can be obtained by calling 1-800-753-5877.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content